NCT05824468 2026-03-10
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
Clinical Trials
82 trialsNCT06114940 2026-03-05
PLUTO
Jinling Hospital, China
Phase 2 Terminated
NCT03983057 2026-02-11
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Zhejiang University
Phase 2 Completed
NCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07392320 2026-02-06
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06281405 2026-01-27
TORCH-iTNT
Fudan University
Phase 2 Recruiting
NCT06468280 2026-01-21
ROSETTE
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07288034 2025-12-17
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT06493240 2025-11-25
NLCCRIT-LARC
Peking University People's Hospital
Phase 2 Completed
NCT04544111 2025-10-07
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07007182 2025-09-05
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT06255223 2025-09-03
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Jinling Hospital, China
Phase 2 Recruiting
NCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
NCT07053150 2025-07-08
CCGLC-018
Tongji Hospital
Phase 2 Not yet recruiting
NCT06728657 2025-06-18
TORCH-G
Fudan University
Phase 2 Suspended
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04821765 2025-05-30
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06908031 2025-05-14
CRIT
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT06928584 2025-04-15
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT04866836 2025-03-21
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Terminated
NCT06840665 2025-02-21
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT06792162 2025-01-24
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Peking University Third Hospital
Phase 2 Recruiting
NCT04518280 2025-01-17
TORCH
Fudan University
Phase 2 Completed
NCT05555888 2025-01-15
TORCH-E
Fudan University
Phase 2 Recruiting
NCT05972655 2025-01-09
mRCAT
Sir Run Run Shaw Hospital
Phase 2 Recruiting
NCT04310397 2024-10-30
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06665087 2024-10-30
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
Fudan University
Phase 2 Not yet recruiting
NCT05522582 2024-10-26
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
Yancheng First People's Hospital
Phase 2 Active not recruiting
NCT05628038 2024-10-01
TORCH-R
Fudan University
Phase 2 Recruiting
NCT03291054 2024-06-11
Epacadostat and Pembrolizumab in Patients With GIST
Columbia University
Phase 2 Terminated
NCT06396637 2024-05-02
PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
Sun Yat-sen University
Phase 2 Recruiting
NCT04301557 2024-04-23
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04430036 2024-04-04
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT04830267 2024-03-28
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT06170710 2023-12-14
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06122493 2023-11-08
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Phase 2 Recruiting
NCT06120127 2023-11-07
IMPROVE
Fudan University
Phase 2 Unknown
NCT05307198 2023-10-10
RAIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04422392 2023-08-30
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Terminated
NCT05961761 2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2 Recruiting
NCT05213884 2023-05-06
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT05556200 2023-04-12
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04030260 2023-03-23
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05097209 2023-03-23
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Guilin Medical University, China
Phase 2 Recruiting
NCT05760196 2023-03-08
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors
Renmin Hospital of Wuhan University
Phase 2 Unknown
NCT05182957 2023-01-31
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04833387 2023-01-11
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05468138 2022-08-26
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
Fudan University
Phase 2 Unknown